论文信息 - A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy. - 字舞流文

A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy.

Chih-Hung Hsu | Y. Chao | A. Cheng | Bang-Bin Chen | Y. Hung | Y. Shao | Ying-Chun Shen | Zhong‐Zhe Lin | R. Lee | C. Hsu | Po-Hsiang Huang